Article

FDA Clears Centricity Vision's IOL positioning system

Author(s):

ZEPTOLink will be introduced at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.

ZEPTOLink is being introduced this weekend at the American Society of Cataract and Refractive Surgery Annual Meeting in San Diego. (Image Courtesy of Adobe Stock)

ZEPTOLink is being introduced this weekend at the American Society of Cataract and Refractive Surgery Annual Meeting in San Diego. (Image Courtesy of Adobe Stock)

Centricity Vision Inc. this week announced it has received 510(k) clearance from the FDA for its ZEPTOLink IOL Positioning System.

According to the company, the platform integrates the ZEPTO precision pulse capsulotomy technology with any phacoemulsification (phaco) system to streamline cataract surgery.

Centricity Vision noted ZEPTO creates an instantaneous capsulotomy with 360-degree IOL overlap for optimal lens positioning and improved outcomes.

Moreover, the company noted the ZEPTOLink platform integrates with any phaco system, saving time and space in the operating room. The technology delivers the same strong, consistent, centered capsulotomy while providing surgeons with complete control via the phaco foot pedal.

ZEPTOLink will be introduced at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.

The company noted ZEPTOLink uses suction and irrigation provided by the phaco system, enabling surgeons to fully control the ZEPTO handpiece apposition, suction, energy delivery, and release using the phaco foot pedal. Key features include:

  • Integration with any phacoemulsification system
  • Small ergonomic console that attaches to any phaco system
  • Modern touchscreen display with voice-supported functions
  • Dedicated ZEPTOLink handpiece for efficient set-up, priming, and operation by a single person all within the sterile field
  • Clinically proven ZEPTO technology for precise, consistent, and centered capsulotomies with 360-degree IOL overlap

Following ASCRS, Centricity Vision is planning a phased approach for the U.S. market roll-out of ZEPTOLink, with a broader commercial launch later this year.

"As a current user, I value the safety, precision, and consistency of a ZEPTO capsulotomy. Now with the phaco integration, ZEPTOLink offers greater workflow efficiency than ever before," said Eric Donnenfeld, MD.

Creating a well-formed, centered capsulotomy is among the most difficult steps of cataract surgery, and it is essential for effective IOL positioning and stability. The company noted that by applying 12 micro-pulses of energy in just 4 milliseconds, ZEPTOLink enables surgeons to center the capsulotomy with 360-degree IOL overlap on the patient's visual axis for improved outcomes1-4.

"By improving IOL centration and operating room productivity, ZEPTOLink will benefit patients and practices alike," said Centricity Vision President and CEO Rob Thornhill said in a news release. "We believe this streamlined surgical solution will help drive the future of automated refractive cataract surgery."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.